الرسائل الموجهة للمختصين الصحيين
الرسائل الموجهة للمختصين الصحيين
| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| FEGONA (Fingolimod) | 2017-08-20 | FEGONA (Fingolimod): Risk related to the effects of FEGONA on the immune system. |
|
| Fingolimod (Gilenya®) | 2016-03-21 | Risks related to the effects on the immune system . |
|
| Xarelto ® (Rivaroxaban) | 2015-12-14 | Warnings and precautions for use to reduce the risk of bleeding.
|
|
| Motilium® (Domperidone) | 2014-09-22 | New recommendations to minimise the cardiac risks . |
|
| Amistop® (Domperidone) | 2014-09-14 | New recommendations to minimise the cardiac risks . |
|
| Mododom® (Domperidone) | 2014-09-14 | New recommendations to minimise the cardiac risks . |
|
| Prokinin® (Domperidone) | 2014-09-07 | New recommendations to minimise the cardiac risks .
|
|
| Arzerra® (ofatumumab) | 2014-07-20 | change to safety information regarding update to hepatitis B virus reactivation warning . |
|
| Arzerra® (ofatumumab) | 2014-07-20 | Safety update on a fatal infusion reaction reported in a patient with Chronic lymphocytic leukemia (CLL) who was treated with intravenous ofatumumab . |
|
| Riacavilol® (Carvedilol) | 2014-07-09 | Important safety update of prescribing information for Carvidol® (Carvedilol)
|
|